Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress


Posted on: 14 Oct 16

CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.

“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”

The following posters have been scheduled for presentation:

NumberPoster TitlePresenterTime
#283Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break modelReynald Lescarbeau, Ph.D.
Computational Scientist, Bioinformatics
October 19, 2016
18:30 - 20:30 pm
12:30 - 2:30 pm ET
#280Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components   David Morrissey, Ph.D.
Chief Technology Officer
October 20, 2016
18:30 - 20:30 pm
12:30 - 2:30 pm ET

#320DNA repair events after cleavage by CRISPR/Cas9 are not randomWalter Strapps, Ph.D.
Senior Director, Biology
October 20, 2016
18:30 - 20:30 pm
12:30 - 2:30 pm ET
#310Translating CRISPR/Cas9 genome editing into therapeuticsTom Barnes, Ph.D.
Chief Scientific Officer
October 20, 2016
18:30 - 20:30 pm
12:30 - 2:30 pm ET

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

GlobeNewswire
globenewswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.